Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Open Access
- 1 May 2018
- journal article
- research article
- Published by Informa UK Limited in Future Oncology
- Vol. 14 (11), 1035-1047
- https://doi.org/10.2217/fon-2017-0616
Abstract
Treatment for relapsed/refractory multiple myeloma (RRMM) remains an unmet need. Isatuximab, an anti-CD38 monoclonal antibody has shown efficacy and tolerability as a monotherapy and combination therapy in Phase I/II studies in RRMM. Here, we describe the design of the Phase III ICARIA-MM study (NCT02990338) which will evaluate isatuximab in combination with pomalidomide (Pom) and low-dose dexamethasone (dex) (Pom/dex) versus Pom/dex alone in RRMM. Patients will be randomized in a 1:1 ratio. The primary endpoint is progression-free survival. Response will be determined by an independent response review committee using IMWG criteria (2016) and safety will be assessed throughout. Approximately 300patients (150 in each arm) are expected to enroll. The first patient was recruited in January 2017 and accrual is ongoing.Keywords
Funding Information
- Celgene
This publication has 39 references indexed in Scilit:
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationJournal of Clinical Oncology, 2014
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple MyelomaClinical Cancer Research, 2013
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaBlood, 2012
- Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialBlood, 2012
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple MyelomaJournal of Clinical Oncology, 2009
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- CD4+CD25+CD127low/− regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progressionClinical Immunology, 2009
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008